About Shield Bio

Shield Bio utilizes ultra-fast sequencing technology to identify and monitor genetic mutations in bacteria that contribute to antibiotic resistance. This approach enables healthcare providers to implement targeted treatments, reducing the prevalence of ineffective antibiotics and improving patient outcomes.

<problem> The rise of antibiotic-resistant bacteria poses a significant threat to global health, making infections harder to treat and increasing the risk of complications and mortality. Traditional methods for identifying antibiotic resistance genes are often slow and lack the sensitivity needed for timely clinical decision-making. This delay can lead to the overuse of broad-spectrum antibiotics, further exacerbating the problem of resistance. </problem> <solution> Shield Bio offers a rapid, high-throughput sequencing platform for the detection and monitoring of antibiotic resistance genes in bacterial pathogens. Their technology enables healthcare providers to quickly identify specific resistance mutations, allowing for targeted antibiotic therapy and improved patient outcomes. By providing actionable insights into the genetic makeup of bacterial infections, Shield Bio helps to reduce the reliance on broad-spectrum antibiotics and promotes antimicrobial stewardship. The platform's speed and sensitivity facilitate early detection of resistance, enabling proactive infection control measures and preventing the spread of resistant strains. </solution> <features> - Ultra-fast DNA sequencing technology for rapid identification of antibiotic resistance genes - Comprehensive database of known resistance mutations for accurate detection - High-throughput platform capable of processing multiple samples simultaneously - User-friendly software interface for easy data analysis and interpretation - Integration with existing laboratory information systems (LIS) for seamless workflow - Cloud-based data storage and analysis for secure and accessible results </features> <target_audience> The primary target audience includes hospitals, diagnostic laboratories, and public health organizations involved in infectious disease management and antibiotic stewardship programs. </target_audience>

What does Shield Bio do?

Where is Shield Bio located?

Shield Bio is based in San Jose, United States.

When was Shield Bio founded?

Shield Bio was founded in 2016.

Location

San Jose, United States

Founded

2016

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Shield Bio

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

shieldbio.com

Founded 2016 – San Jose, United States

Funding

No funding information available.

Team

No team information available.

Company Description

Problem

The rise of antibiotic-resistant bacteria poses a significant threat to global health, making infections harder to treat and increasing the risk of complications and mortality. Traditional methods for identifying antibiotic resistance genes are often slow and lack the sensitivity needed for timely clinical decision-making. This delay can lead to the overuse of broad-spectrum antibiotics, further exacerbating the problem of resistance.

Solution

Shield Bio offers a rapid, high-throughput sequencing platform for the detection and monitoring of antibiotic resistance genes in bacterial pathogens. Their technology enables healthcare providers to quickly identify specific resistance mutations, allowing for targeted antibiotic therapy and improved patient outcomes. By providing actionable insights into the genetic makeup of bacterial infections, Shield Bio helps to reduce the reliance on broad-spectrum antibiotics and promotes antimicrobial stewardship. The platform's speed and sensitivity facilitate early detection of resistance, enabling proactive infection control measures and preventing the spread of resistant strains.

Features

Ultra-fast DNA sequencing technology for rapid identification of antibiotic resistance genes

Comprehensive database of known resistance mutations for accurate detection

High-throughput platform capable of processing multiple samples simultaneously

User-friendly software interface for easy data analysis and interpretation

Integration with existing laboratory information systems (LIS) for seamless workflow

Cloud-based data storage and analysis for secure and accessible results

Target Audience

The primary target audience includes hospitals, diagnostic laboratories, and public health organizations involved in infectious disease management and antibiotic stewardship programs.